Isolere Bio receives a Phase I SBIR award from NIH to support application of the IsoTag technology to Lentivirus manufacturing

Written By jeremy hogenbaum

January 24, 2022, Durham, NC Isolere has received its official Notice of Award from NIGMS to fund its SBIR proposal applying the novel IsoTag technology to lentiviral vectors, which are critical, but expensive tools used in CAR-T and other cell therapies. We are thankful for this funding and its role in supporting the technical feasibility demonstrations for more efficient concentration and purification of higher quality lentivirus.

To learn more please contact us here or +1 (719) 322-4394.

jeremy hogenbaum
Previous

Isolere Bio Enters into Research Collaboration Agreement with Oxford Biomedica to Develop Enabling Manufacturing Technology for Lentiviral Vectors
Next

Isolere welcomes Dr. James McGuiness to the team to spearhead our nucleic acids applications!​